Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors

NCT03740256 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT03740256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03740256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Recruiting
Start date
December 14, 2020
Completion date
December 30, 2038
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, breast cancer, cancer of the salivary gland, colorectal cancer, esophageal cancer, gastric cancer, head and neck squamous cell carcinoma, lung cancer, pancreatic adenocarcinoma, solid tumor